All News

Found 573,301 articles

• Bayer Submits Supplemental New Drug Application to FDA for Intrauterine Device (IUD) Mirena® (levonorgestrel-releasing intrauterine system) 52 mg

  10/21/2019

  Bayer, a leader in women's healthcare, announced today the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) to potentially extend the duration of use for its market leading1 intrauterine device (IUD) Mirena® (levonorgestrel-releasing intrauterine system) 52 mg.

• Vertex to Announce Third-Quarter 2019 Financial Results on October 30

  10/21/2019

  To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).

• Mycovia Pharmaceuticals to Present at 2019 BIO Investor Forum

  10/21/2019

  Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced that Chief Executive Officer Patrick Jordan will present at the 2019 BIO Investor Forum being held October 22-23 at the Westin St. Francis in San Francisco, Calif.

• C Spire, University of Mississippi Medical Center debut new mobile health app

  10/21/2019

  C Spire executives and state medical leaders unveiled a new mobile app today that promises to improve access to quick, reliable health care for more people in Mississippi, especially those in rural and underserved areas, with minor ailments.

• NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)

  10/21/2019

  This Committee recommendation will now be reviewed by the European Commission which, if it chooses to affirm the CHMP’s recommendation, will grant a centralized marketing authorization of the vaccine under a unified label valid in 31 European countries.

• Veracyte Announces Clinical Data Demonstrating Clinical Validity and Utility of Percepta Classifier in Lung Cancer Diagnosis When Bronchoscopy Results Are Inconclusive

  10/21/2019

  Data Being Presented at CHEST Annual Meeting 2019

• Brookdale Announces Third Quarter 2019 Earnings Release and Call

  10/21/2019

   Brookdale Senior Living Inc. (NYSE: BKD) announced today that it plans to release its third quarter 2019 financial results after the market closes on Monday, November 4, 2019. 

• SpinalCyte to Present at the 2019 BIO Investor Forum

  10/21/2019

  SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced that Pete O'Heeron, SpinalCyte's Chief Executive Officer, will present at the BIO Investor Forum on Tuesday, October 22, 2019 at 3:45 p.m. PDT in San Francisco, CA.

• Free AmpliVox Pink Podiums and Megaphones Available for Breast Cancer Awareness

  10/21/2019

  October is Breast Cancer Awareness Month, with its signature wearing of pink to help build awareness of prevention and treatment of the disease.

• Teva Settles Track 1 Opioid Cases and Reaches Agreement on Framework to Settle Remaining Litigation

  10/21/2019

  Teva Pharmaceutical Industries Ltd. and its affiliates today announced a settlement agreement with both Cuyahoga and Summit counties of Ohio. The settlement resolves the counties’ claims and removes Teva from the Track 1 opioid litigation.

• Charles River Laboratories Schedules Third-Quarter 2019 Earnings Release and Conference Call

  10/21/2019

  A conference call has been scheduled to discuss this information on Wednesday, November 6th, at 9:00 a.m. ET.

• Amplify Science Earns Prestigious Tier 1 Rating in Louisiana

  10/21/2019

  Amplify, a publisher of next-generation curriculum and assessment programs, announced today that Louisiana rated Amplify Science K–5 as Tier 1, the top rating in the state. Amplify Science is the only K–5 science program in the state to receive a Tier 1 rating

• Mallinckrodt Raises Awareness of Critical Role Respiratory Therapists Play in Patient Care During Respiratory Care Week

  10/21/2019

  There are more than 134,000 respiratory therapists in the U.S. Respiratory therapists work closely as part of medical teams to evaluate, treat and care for patients with breathing or other cardiopulmonary disorders.

• Innate Pharma Announces Closing of Global Offering

  10/21/2019

  INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate Pharma” or the “Company”), today announced the closing of its previously announced global offering to specified categories of investors of an aggregate of 14,375,000 new ordinary shares,

• Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)

  10/21/2019

  Capricor Therapeutics (Nasdaq: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announced today that it will host a Key Opinion Leader (KOL) call on the role of CAP-1002 in the of treatment of Duchenne Muscular Dystrophy (DMD) on Thursday, October 24th at 10:30am Eastern Time.

• Novation Companies Announces Date of 2019 Annual Meeting of Shareholders

  10/21/2019

  Novation Companies, Inc. (NOVC) (“Novation” or the “Company”), which through its subsidiary Healthcare Staffing, Inc. provides outsourced health care staffing and related services in the State of Georgia, is announcing that its 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”) will be held on December 12, 2019, at 10:00 a.m. Central Standard Time in Kansas City.

• BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2020

  10/21/2019

  BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2020

• PFAS Remedial Strategies--Integral Consulting Principal Avram Frankel Chairs Panel at AEHS

  10/21/2019

   Are there better ways to treat or mitigate PFAS—those fluorinated, organic substances that are of increasing public and regulatory concern?

• Exicure to Present at 2019 BIO Investor Forum

  10/21/2019

  The webcast will be archived for approximately 30 days following the event.

• Nymox Reports on Newly Issued Patents and Corporate Developments

  10/21/2019

  Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report very positive fundamental news, that the Company has received several new additional United States, European, and other jurisdictional formal patent issuances covering Fexapotide Triflutate and its use for prostate and urinary tract disorders.